Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895598050> ?p ?o ?g. }
- W2895598050 endingPage "e492" @default.
- W2895598050 startingPage "e479" @default.
- W2895598050 abstract "In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and maintenance regimens (in conjunction with high-dose melphalan and autologous stem cell transplantation [auto-SCT]) after a median of 52 months of follow-up, by comparison with regimens containing classical cytotoxic drugs. In this follow-up analysis, we aimed to determine the long-term effects of thalidomide in induction and maintenance therapy in multiple myeloma.In this open-label, phase 3 randomised controlled trial, patients with recently diagnosed multiple myeloma were recruited from 44 Dutch and Belgian hospitals. Participants had been diagnosed with multiple myeloma of Durie-Salmon stage II or III and were aged 18-65 years. Patients were randomly assigned (1:1) either to receive three 28-day cycles of vincristine (0·4 mg, intravenous rapid infusion on days 1-4), doxorubicin (9 mg/m2, intravenous rapid infusion on days 1-4) and dexamethasone (40 mg, orally on days 1-4, 9-12, and 17-20; control group); or to receive the same regimen, but with thalidomide (200-400 mg, orally on days 1-28) instead of vincristine (thalidomide group). No masking after assignment to intervention was used. Patients were randomly assigned to groups, stratified by centre and treatment policy (one vs two courses of high-dose melphalan and auto-SCT). After stem cell harvest, patients received one or two courses of 200 mg/m2 melphalan intravenously with auto-SCT. Patients with at least a partial response to high-dose melphalan and auto-SCT were eligible for maintenance therapy, starting 2-3 months after high-dose melphalan. Patients in the control group received maintenance therapy with interferon alfa (3 × 106 international units, subcutaneously, three times weekly). Patients in the thalidomide group received thalidomide as maintenance therapy (50 mg, orally, daily). Maintenance therapy was given until relapse, progression, or the occurrence of adverse events. The primary endpoint of the study was event-free survival (EFSc; censored at allogeneic stem cell transplantation), analysed by intention to treat. The study is closed for enrolment and this Article represents the final analysis. This trial was registered with the Netherlands Trial Register, number NTR238.Between Nov 27, 2001 and May 31, 2005, 556 patients were enrolled in the study, of whom 536 (96%) were eligible for evaluation and were randomly allocated (268 [50%] to the control group and 268 [50%] to the thalidomide group). These 536 patients were assessed for the primary endpoint of EFSc. At an extended median follow-up of 129 months (IQR 123-136), EFSc was significantly longer in the thalidomide group compared with the control group (multivariate analysis hazard ratio [HR] 0·62, 95% CI 0·50-0·77; p<0·0001). Thalidomide maintenance was stopped because of toxicity in 65 (42%) of 155 patients in the thalidomide group (neuropathy in 49 [75%] patients, skin reactions in four [6%] patients, fatigue in two [3%] patients, and as other symptoms [such as abdominal pain, pancreatitis, and dyspnoea] in ten [15%] patients). 24 (27%) of 90 patients in the control group discontinued protocol treatment during maintenance therapy with interferon alfa because of toxicity (five [21%] patients with psychiatric side-effects, five [21%] patients with flu-like symptoms, four [17%] patients with haematological toxicity [thrombocytopenia and leucocytopenia], three [13%] patients with skin reactions, and seven [29%] patients with other symptoms [such as infections, cardiomyopathy, and headache]). The frequency of second primary malignancies was similar in both groups. There were 23 second primary malignancies in 17 patients in the control group and 29 second primary malignancies in 24 patients in the thalidomide group. There were 19 treatment-related deaths in the control group, and 16 treatment-related deaths in the thalidomide group.Our data indicate that thalidomide-based treatment could be a treatment option for patients with multiple myeloma who are eligible for auto-SCT who live in countries without access to proteasome inhibitors or lenalidomide. However, careful follow-up and timely dose adjustments are important to prevent the development of thalidomide-induced neurotoxicity.The Dutch Cancer Foundation." @default.
- W2895598050 created "2018-10-12" @default.
- W2895598050 creator A5002972322 @default.
- W2895598050 creator A5004217461 @default.
- W2895598050 creator A5006799794 @default.
- W2895598050 creator A5015822462 @default.
- W2895598050 creator A5023165076 @default.
- W2895598050 creator A5024312792 @default.
- W2895598050 creator A5032770450 @default.
- W2895598050 creator A5036293139 @default.
- W2895598050 creator A5037330439 @default.
- W2895598050 creator A5040082277 @default.
- W2895598050 creator A5047262318 @default.
- W2895598050 creator A5049413660 @default.
- W2895598050 creator A5050532707 @default.
- W2895598050 creator A5056550523 @default.
- W2895598050 creator A5058429057 @default.
- W2895598050 creator A5058837783 @default.
- W2895598050 creator A5069712875 @default.
- W2895598050 creator A5070900615 @default.
- W2895598050 creator A5082157943 @default.
- W2895598050 creator A5083385949 @default.
- W2895598050 creator A5087955804 @default.
- W2895598050 date "2018-10-01" @default.
- W2895598050 modified "2023-10-16" @default.
- W2895598050 title "Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial" @default.
- W2895598050 cites W1902692042 @default.
- W2895598050 cites W1985864219 @default.
- W2895598050 cites W2006452574 @default.
- W2895598050 cites W2014946770 @default.
- W2895598050 cites W2021478552 @default.
- W2895598050 cites W2022248147 @default.
- W2895598050 cites W2026448323 @default.
- W2895598050 cites W2028195916 @default.
- W2895598050 cites W2036555006 @default.
- W2895598050 cites W2039511225 @default.
- W2895598050 cites W2044436186 @default.
- W2895598050 cites W2057998903 @default.
- W2895598050 cites W2076668534 @default.
- W2895598050 cites W2080302923 @default.
- W2895598050 cites W2086653135 @default.
- W2895598050 cites W2088540908 @default.
- W2895598050 cites W2090310344 @default.
- W2895598050 cites W2093757149 @default.
- W2895598050 cites W2101414374 @default.
- W2895598050 cites W2104200322 @default.
- W2895598050 cites W2104993929 @default.
- W2895598050 cites W2120362266 @default.
- W2895598050 cites W2121399230 @default.
- W2895598050 cites W2133739087 @default.
- W2895598050 cites W2134877860 @default.
- W2895598050 cites W2135514413 @default.
- W2895598050 cites W2136373453 @default.
- W2895598050 cites W2136541422 @default.
- W2895598050 cites W2146607984 @default.
- W2895598050 cites W2150254829 @default.
- W2895598050 cites W2151989390 @default.
- W2895598050 cites W2158106888 @default.
- W2895598050 cites W2162771614 @default.
- W2895598050 cites W2167021542 @default.
- W2895598050 cites W2169210165 @default.
- W2895598050 cites W2182681254 @default.
- W2895598050 cites W2193716145 @default.
- W2895598050 cites W2316160054 @default.
- W2895598050 cites W2319764074 @default.
- W2895598050 cites W2343386476 @default.
- W2895598050 cites W2512106959 @default.
- W2895598050 cites W2528329272 @default.
- W2895598050 cites W2531107174 @default.
- W2895598050 cites W2604776612 @default.
- W2895598050 cites W2606664616 @default.
- W2895598050 cites W2613844594 @default.
- W2895598050 cites W2727891259 @default.
- W2895598050 cites W2732548543 @default.
- W2895598050 cites W2737964630 @default.
- W2895598050 cites W2746367132 @default.
- W2895598050 cites W2761865305 @default.
- W2895598050 cites W2767256995 @default.
- W2895598050 cites W2785372400 @default.
- W2895598050 cites W4241368398 @default.
- W2895598050 cites W4250758119 @default.
- W2895598050 doi "https://doi.org/10.1016/s2352-3026(18)30149-2" @default.
- W2895598050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30290905" @default.
- W2895598050 hasPublicationYear "2018" @default.
- W2895598050 type Work @default.
- W2895598050 sameAs 2895598050 @default.
- W2895598050 citedByCount "22" @default.
- W2895598050 countsByYear W28955980502018 @default.
- W2895598050 countsByYear W28955980502019 @default.
- W2895598050 countsByYear W28955980502020 @default.
- W2895598050 countsByYear W28955980502021 @default.
- W2895598050 countsByYear W28955980502022 @default.
- W2895598050 crossrefType "journal-article" @default.
- W2895598050 hasAuthorship W2895598050A5002972322 @default.
- W2895598050 hasAuthorship W2895598050A5004217461 @default.
- W2895598050 hasAuthorship W2895598050A5006799794 @default.
- W2895598050 hasAuthorship W2895598050A5015822462 @default.
- W2895598050 hasAuthorship W2895598050A5023165076 @default.